Dr. Kelly on the Toxicity Profile in CheckMate-227 in NSCLC

Karen Kelly, MD
Published: Monday, Sep 19, 2016



Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.

The study assessed nivolumab (Opdivo), nivolumab plus ipilimumab (Yervoy), nivolumab plus platinum-doublet chemotherapy, and platinum-doublet chemotherapy alone as different treatment options for patients with non-small cell lung cancer (NSCLC).

The biggest concerns for toxicity lie in the ipilimumab arm, says Kelly. Some of the adverse events with this drug included colitis and hepatitis. Given the fact that these drug combinations have been evaluated in other cancer types, physicians already have an idea of how to manage such toxicities. However, Kelly emphasizes that it is important to note that patients with lung cancer are often older and have more comorbidities. Therefore, there is still a bit of a learning curve in managing adverse events in this particular patient population.


Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.

The study assessed nivolumab (Opdivo), nivolumab plus ipilimumab (Yervoy), nivolumab plus platinum-doublet chemotherapy, and platinum-doublet chemotherapy alone as different treatment options for patients with non-small cell lung cancer (NSCLC).

The biggest concerns for toxicity lie in the ipilimumab arm, says Kelly. Some of the adverse events with this drug included colitis and hepatitis. Given the fact that these drug combinations have been evaluated in other cancer types, physicians already have an idea of how to manage such toxicities. However, Kelly emphasizes that it is important to note that patients with lung cancer are often older and have more comorbidities. Therefore, there is still a bit of a learning curve in managing adverse events in this particular patient population.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x